Logo image of RN.MI

RISANAMENTO SPA (RN.MI) Stock Fundamental Analysis

BIT:RN - Euronext Milan - IT0001402269 - Common Stock - Currency: EUR

0.0208  0 (-0.95%)

Fundamental Rating

1

Overall RN gets a fundamental rating of 1 out of 10. We evaluated RN against 73 industry peers in the Real Estate Management & Development industry. RN may be in some trouble as it scores bad on both profitability and health. RN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

RN had negative earnings in the past year.
In the past year RN has reported a negative cash flow from operations.
RN had negative earnings in 4 of the past 5 years.
RN had negative operating cash flow in 4 of the past 5 years.
RN.MI Yearly Net Income VS EBIT VS OCF VS FCFRN.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

RN has a Return On Assets of -31.32%. This is amonst the worse of the industry: RN underperforms 86.30% of its industry peers.
RN has a worse Return On Equity (-918.62%) than 87.67% of its industry peers.
Industry RankSector Rank
ROA -31.32%
ROE -918.62%
ROIC N/A
ROA(3y)-10.95%
ROA(5y)-7.97%
ROE(3y)-342.17%
ROE(5y)-214.79%
ROIC(3y)N/A
ROIC(5y)N/A
RN.MI Yearly ROA, ROE, ROICRN.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

1.3 Margins

RN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RN.MI Yearly Profit, Operating, Gross MarginsRN.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

More info and screens

2

2. Health

2.1 Basic Checks

RN does not have a ROIC to compare to the WACC, probably because it is not profitable.
RN has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, RN has about the same amount of shares outstanding.
The debt/assets ratio for RN is higher compared to a year ago.
RN.MI Yearly Shares OutstandingRN.MI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B
RN.MI Yearly Total Debt VS Total AssetsRN.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

RN has an Altman-Z score of -1.36. This is a bad value and indicates that RN is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -1.36, RN is not doing good in the industry: 84.93% of the companies in the same industry are doing better.
RN has a Debt/Equity ratio of 0.38. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.38, RN is doing good in the industry, outperforming 68.49% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.38
Debt/FCF N/A
Altman-Z -1.36
ROIC/WACCN/A
WACC8.03%
RN.MI Yearly LT Debt VS Equity VS FCFRN.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

RN has a Current Ratio of 1.67. This is a normal value and indicates that RN is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.67, RN perfoms like the industry average, outperforming 56.16% of the companies in the same industry.
A Quick Ratio of 0.36 indicates that RN may have some problems paying its short term obligations.
RN has a worse Quick ratio (0.36) than 69.86% of its industry peers.
Industry RankSector Rank
Current Ratio 1.67
Quick Ratio 0.36
RN.MI Yearly Current Assets VS Current LiabilitesRN.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

0

3. Growth

3.1 Past

RN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -500.00%.
Looking at the last year, RN shows a very negative growth in Revenue. The Revenue has decreased by -99.98% in the last year.
RN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -59.85% yearly.
EPS 1Y (TTM)-500%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-212.12%
Revenue 1Y (TTM)-99.98%
Revenue growth 3Y-39.29%
Revenue growth 5Y-59.85%
Sales Q2Q%-99.74%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RN.MI Yearly Revenue VS EstimatesRN.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RN. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RN.MI Price Earnings VS Forward Price EarningsRN.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RN.MI Per share dataRN.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.01 -0.02

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RISANAMENTO SPA

BIT:RN (7/11/2025, 7:00:00 PM)

0.0208

0 (-0.95%)

Chartmill FA Rating
GICS SectorReal Estate
GICS IndustryGroupEquity Real Estate Investment Trusts (REITs)
GICS IndustryReal Estate Management & Development
Earnings (Last)04-30 2025-04-30
Earnings (Next)07-28 2025-07-28
Inst Owners48.91%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap37.46M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 279.53
P/FCF N/A
P/OCF N/A
P/B 7.25
P/tB 7.33
EV/EBITDA N/A
EPS(TTM)-0.03
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0
BVpS0
TBVpS0
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -31.32%
ROE -918.62%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-10.95%
ROA(5y)-7.97%
ROE(3y)-342.17%
ROE(5y)-214.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.38
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 520.8%
Cap/Sales 1064.93%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.67
Quick Ratio 0.36
Altman-Z -1.36
F-Score1
WACC8.03%
ROIC/WACCN/A
Cap/Depr(3y)179.32%
Cap/Depr(5y)109.66%
Cap/Sales(3y)364.44%
Cap/Sales(5y)228.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-500%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-212.12%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-99.98%
Revenue growth 3Y-39.29%
Revenue growth 5Y-59.85%
Sales Q2Q%-99.74%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-299.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-176.71%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-172.93%
OCF growth 3YN/A
OCF growth 5YN/A